| Bioactivity | BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC50=1.9 nM) with anticancer activity. BET-IN-20 can promote acute myeloid leukemia (AML) cell apoptosis and arrest the cell cycle in the G0/G1 phase. BET-IN-20 also inhibits c-Myc and CDK6 and enhances PARP cleavage[1]. |
| Target | IC50: 1.9 nM (BRD4 BD1) |
| Name | BET-IN-20 |
| CAS | 1300735-76-5 |
| Formula | C25H24N4O2 |
| Molar Mass | 412.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yu S et al. Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo [4, 5-c] quinnolin-7-yl)-3, 5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation[J]. European Journal of Medicinal Chemistry, 2023: 115924. |
BET-IN-20
CAS: 1300735-76-5 F: C25H24N4O2 W: 412.48
BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC50=1.9 nM) with anticancer activity. BET-IN-20 can promote acute
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.